GERN Message Board Post 8894536 | Geron Corporation
home / stock / gern / gern message board
astuteinsights
(investorshub)
Posted on: Jan/14/2023 18:19:49
Source: investorshub
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170946950
Believing in the drug is not enough. Management
News, Short Squeeze, Breakout and More Instantly...
-
RYTELO, for both RS+ and RS- patients, has a Category 1 recommendation for second-line treatment and a Category 2A recommendation for first-line treatment of patients who are ESA ineligible (serum EPO >500 mU/mL) Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical ...
-
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that Anil Kapur, Executive Vice President, Corporate Strategy and Chief Commercial Officer, will depart the Company on August 31, 2024, to ...
-
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its second quarter 2024 financial results and business highlights before the market opens on Thursday, August 8, 2024 via press release, which will be available on the Company ...